FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting
The Maestro Brain Model reportedly provides automated identification, quantification and labeling of brain structures on magnetic resonance imaging (MRI).
Offering the promise of more efficient reporting of findings from magnetic resonance imaging (MRI) of the brain, the Maestro Brain Model has garnered 510(k) clearance from the Food and Drug Administration (FDA), according to the software’s manufacturer ClearPoint Neuro.
Combining deformable surfaces with active shape models and machine learning, the Maestro Brain Model can provide neuroradiologists with automated labeling as well as shape and volumetric quantification of brain structures on MRI scans.
ClearPoint Neuro said the anatomical segment analysis tool emerged from research examining volumetric and shape abnormalities caused by mild traumatic brain injuries. Noting cross-validation of the technology with more than 1,000 MRI scans, the company noted the Maestro Brain Model offers accurate and highly reproducible results.
The company says future applications of the Maestro Brain Model may facilitate targeted treatment of brain injuries
“Our plan is to quantify drug delivery using intraoperative imaging and simulate patient-specific infusions in targeted brain regions,” explained Lyubomir Zagorchev, a vice-president of Clinical Science and Applications at ClearPoint Neuro. “The unique shape representation in (the Maestro Brain Model) will provide reproducible lead placement for deep brain stimulation and micro electrode recording. Surface meshes of segmented anatomical regions will define safety zones and optimal trajectories for patient-specific laser ablations.”
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.
Study Shows Benefits of AI in Detecting Lung Cancer Risk in Non-Smokers
November 22nd 2023Artificial intelligence (AI) assessments of chest X-rays identified 28 percent of a 17,000 plus cohort of never-smokers as being at high-risk for lung cancer, according to research to be presented at the annual Radiological Society of North America (RSNA) conference next week.
